Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
06 déc. 2022 06h30 HE
|
Editas Medicine, Inc.
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with...
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
01 déc. 2022 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday,...
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
17 nov. 2022 07h15 HE
|
Editas Medicine, Inc.
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients ...
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
02 nov. 2022 06h30 HE
|
Editas Medicine, Inc.
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and...
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
26 oct. 2022 06h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
13 oct. 2022 06h00 HE
|
Editas Medicine, Inc.
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated...
Editas Medicine to Participate in Upcoming Investor Conferences
01 sept. 2022 06h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
03 août 2022 06h29 HE
|
Editas Medicine, Inc.
Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease;...
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
27 juil. 2022 06h30 HE
|
Editas Medicine, Inc.
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a...
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
26 juil. 2022 06h26 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...